Metrics to compare | 217330 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship217330PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.1x | −4.2x | −0.4x | |
PEG Ratio | −0.18 | −0.08 | 0.00 | |
Price/Book | 2.0x | 1.4x | 2.6x | |
Price / LTM Sales | 2.5x | 3.3x | 3.0x | |
Upside (Analyst Target) | - | 112.2% | 51.9% | |
Fair Value Upside | Unlock | 23.9% | 9.4% | Unlock |
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.